ASX healthcare stock that needs to be watched
Recent updates from Biome Australia reflect progress across proprietary research, operating performance and international distribution signalling continued execution across key strategic priorities.
Biome Australia Limited (ASX: BIO)
continues to make steady progress on both commercial execution and long-term product innovation marked by recent developments in its Canadian expansion and research pipeline.
The company has secured distribution for its entire Activated Probiotics range on Fullscript Canada, a leading practitioner to patient platform serving over 100,000 healthcare practitioners and more than 5 million patients across North America.
This partnership complements Biome’s existing relationship with Ecotrend Ecologics enabling comprehensive coverage of the Canadian practitioner market through both traditional wholesale and direct to patient digital channels.
The dual-channel model reduces friction for practitioners and improves accessibility of Biome’s products regardless of their preferred dispensing method.
The company delivered its strongest quarterly performance to date in Q2 FY26. Quarterly revenue increased 41% year on year to $6.5 million while rolling twelve-month revenue reached approximately $22 million.
The company reported its eighth consecutive quarter of the positive EBITDA with Q2 EBITDA of around $1.0 million. Gross margins remained above 61%, supporting the operating leverage as scale increases.
Strong cash generation allowed the Biome to repay working capital facilities while growing its cash balance to $3.36 million.
On 3 February 2026 Biome received the ethics approval to commence its first human clinical trial on its proprietary probiotic strain, Lactobacillus plantarum BMB18.
The randomised double-blind placebo-controlled study will recruit 240 participants and investigate digestive, sleep and mood outcomes. The trial is fully funded within the existing R&D budget and represents key step in validating Biome owned intellectual property.
Ownership of clinically validated proprietary strain has the potential to support new product development enhance competitive positioning and strengthen the underlying asset base over time.
Overall, Biome is progressing across multiple strategic pillars simultaneously distribution expansion, financial discipline and scientific validation. While execution and clinical outcomes will remain key variables to monitor recent developments indicate continued momentum in building a scalable evidence-based microbiome health platform.
(Source: Company Reports)
Get Your Free Report on Top 5 ASX Stocks on WhatsApp
Instant Access. No Credit Card Required.
Receive on WhatsApp
Checkout Our Recommendation for free - 7 days free trial
Start Free TrialASX Stock Research & Recommendations — 7‑day free trial
Independent, analyst‑driven insights.
- Stock of the week report
- Daily Analysis Report
- No credit card required
Get Your FREE Report
Discover the Top ASX Stocks to Invest In 2026!
Expert Analysis of Top-Performing ASX Stocks
Market Insights and In-Depth Research
Buy, Sell, And Hold Recommendations
Almost There!
Enter your details to download the report
Success!
Preparing your download...
Latest Article
Disclaimer
Veye Pty Ltd(ABN 58 623 120 865), holds (AFSL No. 523157 ). All information provided by Veye Pty Ltd through its website, reports, and newsletters is general financial product advice only and should not be considered a personal recommendation to buy or sell any asset or security. Before acting on the advice, you should consider whether it’s appropriate to you, in light of your objectives, financial situation, or needs. You should look at the Product Disclosure Statement or other offer document associated with the security or product before making a decision on acquiring the security or product. You can refer to our Terms & Conditions and Financial Services Guide for more information. Any recommendation contained herein may not be suitable for all investors as it does not take into account your personal financial needs or investment objectives. Although Veye takes the utmost care to ensure accuracy of the content and that the information is gathered and processed from reliable resources, we strongly recommend that you seek professional advice from your financial advisor or stockbroker before making any investment decision based on any of our recommendations. All the information we share represents our views on the date of publishing as stocks are subject to real time changes and therefore may change without notice. Please remember that investments can go up and down and past performance is not necessarily indicative of future returns. We request our readers not to interpret our reports as direct recommendations. To the extent permitted by law, Veye Pty Ltd excludes all liability for any loss or damage arising from the use of this website and any information published (including any indirect or consequential loss, any data loss, or data corruption) (as mentioned on the website www.veye.com.au), and confirms that the employees and/or associates of Veye Pty Ltd do not hold positions in any of the financial products covered on the website on the date of publishing this report. Veye Pty Ltd hereby limits its liability, to the extent permitted by law to the resupply of services.
